Completed
"First-in-human" Study To Assess the Safety and Tolerability of PBF-680 in Male Healthy Volunteers
NCT01845181
- Conditions
- Asthma, Bronchial Diseases, Chronic Disease, +11 more
- Locations
-
- Palobiofarma S.L. (molecule owner) Mataró, Barcelona, Spain
- CIM-Sant Pau. Hospital de la Santa Creu i Sant Pau Barcelona, Catalonia, Spain